Placental tissue preservation liquid and preparation method thereof

A technology for placental tissue and preservation solution, applied in the field of placental tissue preservation solution and preparation thereof, can solve the problems of high price of serum-free medium, incapability of mass production, increased use risk, etc. Conducive to large-scale mass production and the effect of inhibiting microbial contamination

Inactive Publication Date: 2019-02-22
江苏赛尔时代健康产业有限公司
View PDF8 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Previously, there was a patent to preserve isolated placenta by adding penicillin, streptomycin, umbilical plasma, AIM-V serum-free medium, glucose, dextran, amino acids and other substances to PBS or DMEM / F12. And the steps are cumbersome. After penicillin and streptomycin are formulated into a solution, the validity period is short, and the β-lactam ring of penicillin will be hydrolyzed under solution conditions, and the ring-opened compound formed has high allergenicity, which increases the risk of use
The components of umbilical cord plasma are complex, and there are individual differences, so they cannot be mass-produced. AIM~V serum-free medium is relatively expensive, with complex components, variability and nutrient loss when stored at room temperature for a long time

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Placental tissue preservation liquid and preparation method thereof
  • Placental tissue preservation liquid and preparation method thereof
  • Placental tissue preservation liquid and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] The embryo tissue preservation solution of the present invention, every 100mL placental tissue preservation solution comprises the following components:

[0038] Serum Replacement 500mg

[0039] Gentamicin 80000U

[0040] Amphotericin B 1.5mg

[0041] Ascorbyl Phosphate Magnesium Salt Hydrate 25mg

[0042] Trehalose 60mg

[0043] Lithium Heparin 2000U

[0044] Glucose 4.765g.

[0045] Concrete preparation steps are as follows:

[0046] Add 0.5mL of serum replacement to 95.3mL of 5% glucose injection, 1 tube of 2 mL of gentamicin (80000U / mL), 0.5mL of 3mg / mL amphotericin B, 1mL of magnesium ascorbyl phosphate saline compound (25mg / mL), 0.2mL trehalose (300mg / mL) and 0.5mL lithium heparin (4000U / mL) to obtain a placenta preservation solution, put it into a 125 mL sterile collection bottle, and store it at 4°C or at room temperature.

Embodiment 2

[0048] The embryo tissue preservation solution of the present invention, every 100mL placental tissue preservation solution comprises the following components:

[0049] Serum Replacement 1g

[0050] Gentamicin 80000U

[0051] Amphotericin B 2.25mg

[0052] Ascorbyl Phosphate Magnesium Salt Hydrate 37.5mg

[0053] Trehalose 150mg

[0054] Lithium Heparin 3000U

[0055] Glucose 4.675g.

[0056] Concrete preparation steps are as follows:

[0057]Add 1 mL of serum replacement to 93.5 mL of 5% glucose injection, one 2 mL tube of gentamicin (80,000 U / mL), 0.75 mL of 3 mg / mL amphotericin B, and 1.5 mL of magnesium ascorbyl phosphate for hydration Placenta preservation solution (25mg / mL), 0.5mL trehalose (300mg / mL) and 0.75mL lithium heparin (4000U / mL) were obtained, put into a 125 mL sterile collection bottle, and stored at 4°C or at room temperature.

Embodiment 3

[0059] The embryo tissue preservation solution of the present invention, every 100mL placental tissue preservation solution comprises the following components:

[0060] Serum Replacement 2g

[0061] Gentamicin 80000U

[0062] Amphotericin B 3mg

[0063] Ascorbyl Phosphate Magnesium Salt Hydrate 50mg

[0064] Trehalose 300mg

[0065] Lithium Heparin 4000U

[0066] Glucose 4.55g.

[0067] Concrete preparation steps are as follows:

[0068] Add 2mL of serum replacement to 91mL of 5% glucose injection, one 2mL gentamicin (80000U / mL), 1mL amphotericin B with a concentration of 3mg / mL, 2mL magnesium ascorbyl phosphate hydrate (25 mg / mL), 1 mL trehalose (300 mg / mL) and 1 mL lithium heparin (4000 U / mL) to obtain a placenta preservation solution, put it into a 125 mL sterile collection bottle, and store at 4°C or at room temperature.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a placental tissue preservation liquid and a preparation method thereof. The placental tissue preservation liquid includes glucose injection, a serum replacement, gentamicin, amphotericin, trehalose and heparin lithium. The preparation method of the placental tissue preservation liquid includes adding the serum replacement, gentamicin, amphotericin B, magnesium ascorbyl phosphate hydrate, trehalose and heparin lithium into the glucose injection, wherein final concentrations of the ingredients are 0.5-2%, 800 U / mL, 15-30 ug / mL, 0.25-0.5 mg / mL, 0.6-3 mg / mL, and 20-40 U / mL. The placental tissue preservation liquid has clear composition and balanced nutrition, has no evident toxic and side effects on cells, can well maintain activity of in-vitro placental cells, and iseffective in preventing contamination of exogenous microorganisms introduced in the acquisition and transport steps.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to a placental tissue preservation solution and a preparation method thereof. Background technique [0002] Mesenchymal stem cells are a type of cells with self-renewal and multi-directional differentiation potential, also known as multipotential stromal cells, or MSCs for short, are a type of pluripotent stem cells belonging to the mesoderm, which mainly exist in connective tissue and organ interstitium. Including: bone marrow, umbilical cord, fat, mucous membrane, bone, muscle, placenta, etc. Under suitable conditions, it can differentiate into various tissue cells such as fat, bone, and cartilage. Compared with MSCs from other sources, placenta-derived mesenchymal stem cells are easy to obtain and have no moral and ethical disputes. High, easy to expand and passage, and at the same time, there are no problems such as matching and rejection. It is extremely suitable for clinical res...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A01N1/02
CPCA01N1/021A01N1/0226
Inventor 王军霞谢再东潘春雷殷鉴强刘定生
Owner 江苏赛尔时代健康产业有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap